ThermoGenesis Holdings (ThermoGenesis Holdings) Total Liabilities : $14.82 Mil (As of Dec. 2023)

View and export this data going back to 1987. Start your Free Trial

What is ThermoGenesis Holdings Total Liabilities?

ThermoGenesis Holdings's Total Liabilities for the quarter that ended in Dec. 2023 was $14.82 Mil.

ThermoGenesis Holdings's quarterly Total Liabilities declined from Jun. 2023 ($14.98 Mil) to Sep. 2023 ($12.66 Mil) but then increased from Sep. 2023 ($12.66 Mil) to Dec. 2023 ($14.82 Mil).

ThermoGenesis Holdings's annual Total Liabilities declined from Dec. 2021 ($17.26 Mil) to Dec. 2022 ($16.06 Mil) and declined from Dec. 2022 ($16.06 Mil) to Dec. 2023 ($14.82 Mil).

ThermoGenesis Holdings Total Liabilities Historical Data

The historical data trend for ThermoGenesis Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ThermoGenesis Holdings Total Liabilities Chart

ThermoGenesis Holdings Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

14.30

14.99

17.26

16.06

14.82

ThermoGenesis Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															16.06	14.74	14.98	12.66	14.82

ThermoGenesis Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ThermoGenesis Holdings's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.762	+	(2.9	+	0.027
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.127	+	0)
	=	14.82

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	11.232	-	-3.584
	=	14.82

ThermoGenesis Holdings's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.762	+	(2.9	+	0.027
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.127	+	0)
	=	14.82

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	11.232	-	-3.584
	=	14.82

ThermoGenesis Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

ThermoGenesis Holdings (ThermoGenesis Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (NAS:THMO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

THR:Germany

Address

2711 Citrus Road, Rancho Cordova, CA, USA, 95742

Website

https://www.thermogenesis.com

ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.

Executives

Xiaochun Xu	director	2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Biao Xi	director	C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
James Xu	director	2453 S. ARCHER AVE, SUITE B, CHICAGO IL 60616
Haihong Zhu	director	2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Debra Donaghy	director	C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS RD., RANCHO CORDOVA CA 95742
Boyalife (hong Kong) Ltd	10 percent owner	2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Thomis Joseph	director	MALEIZENSTRAAT 66, HERENT C9 B-3020
Boyalife Asset Holding Ii, Inc.	10 percent owner	2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Boyalife Group, Inc.	10 percent owner	2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Russell M Medford	director	7935 FAWNDALE WAY, ATLANTA GA 30350
Mark Westgate	director	350 CORPORATE BOULEVARD, ROBBINSVILLE NJ 08691
Jeffery Cauble	officer: Principal Accounting Officer	2711 CITRUS CT., RANCHO CORDOVA CA 95742
Vivian H Liu	director
Boyalife Investment Inc.	10 percent owner	2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Mark Bagnall	director	3876 BAY CENTER PLACE, HAYWARD CA 94545